Barrow doctor says new Alzheimer's drug called Lecanemab is not for every patient

A new drug to treat cognitive decline and help fight the cause of brain deterioration in those with Alzheimer’s is now poised for Food and Drug Administration approval.It’s called Lecanemab, and it works by attacking sticky plaque buildup in the brain, sort of how cholesterol-fighting drugs work.But, Dr. Pierre Tariot with Barrow Neurological Institute said the drug is not for

Related Keywords

Pierre Tariot , Barrow Neurological Institute , Drug Administration ,